Randomized double-blind clinical comparison of sodium ibandronate and pamidronate disodium for treatment of 141 patients with malignant tumor ostealgia
Objective To evaluate the therapeutic effect and potential adverse effects of sodium ibandronate (SI) in patients with malignant tumor
Methods Patients were randomly classified into two groups. Group A (SI) of 68 patients who received 4 mg SI i.v., and 73 patients
in Group B (pamidronate disodium [PD]) who received 60 mg PD i.v. A randomized, double-blind method, with PD as a positive
drug control, was used to assess changes in bone pain and adverse effects over a three-week period.
Results A total of 141 patients were enrolled in the study, with 136 cases of appraisable efficacy. The effective rate was 72.3% (47/65)
in Group A, and 63.4% (45/71) in Group B. There was no significant difference in efficacy or adverse effects between the 2
Conclusion The SI injection, with a pronounced effect, can relieve bone pain caused by osseous metastasis from a malignant tumor. The
curative and adverse effects were similar compared to PD.